Cost effectiveness analysis of allogeneic, just-in-time expansion of mesenchymal stem cells with PLUS™ human platelet lysate for a clinical trial

Bandeiras, Cátia; Koç, Jane Reese; Ma, Yiwei; Samberg, Meghan E.; Finkelstein, Stan N.; Ferreira, Frederico Castelo

doi:10.1016/j.jcyt.2018.02.166

Cited by 4 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A strong MSCs therapy clinical translation cannot be realized without considering the relevant aspects of the product cycle and its related cost. Currently, the costs of MSCs manufacturing vary between 15,000 and 30,000 $/€ per 1–5 million cGMP‐MSCs per kilogram . These manufacturing costs then have to be added to the expenses related to the clinical delivery and the follow up.…”

Section: Business Costs and Mscs Clinical Translationmentioning

confidence: 99%

Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review

Mastrolia

Foppiani

Murgia

et al. 2019

Stem Cells Translational Medicine

218

182

View full text Add to dashboard Cite

Summary Identified 50 years ago, mesenchymal stromal/stem cells (MSCs) immediately generated a substantial interest among the scientific community because of their differentiation plasticity and hematopoietic supportive function. Early investigations provided evidence of a relatively low engraftment rate and a transient benefit for challenging congenital and acquired diseases. The reasons for these poor therapeutic benefits forced the entire field to reconsider MSC mechanisms of action together with their ex vivo manipulation procedures. This phase resulted in advances in MSCs processing and the hypothesis that MSC‐tissue supportive functions may be prevailing their differentiation plasticity, broadening the spectrum of MSCs therapeutic potential far beyond their lineage‐restricted commitments. Consequently, an increasing number of studies have been conducted for a variety of clinical indications, revealing additional challenges and suggesting that MSCs are still lagging behind for a solid clinical translation. For this reason, our aim was to dissect the current challenges in the development of still promising cell types that, after more than half a century, still need to reach their maturity. Stem Cells Translational Medicine 2019;8:1135–1148

show abstract

Section: Business Costs and Mscs Clinical Translationmentioning

confidence: 99%

Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review

Mastrolia

Foppiani

Murgia

et al. 2019

Stem Cells Translational Medicine

218

182

View full text Add to dashboard Cite

show abstract

“…Lastly, any remaining fragments are removed, the pool is aliquoted and controlled before release. In recent years multiple commercial options have become available and some of them have already been under investigation in comparison to FBS (see Table 2 ) [ 131 , 132 , 133 , 134 ]. Suppliers include Sigma-Aldrich, Merck, PL Bioscience, Compass Biomedical and Stemcell Technologies.…”

Section: Human Platelet Lysatementioning

confidence: 99%

Towards Physiologic Culture Approaches to Improve Standard Cultivation of Mesenchymal Stem Cells

Nikolits

Nebel

Egger

et al. 2021

Cells

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are of great interest for their use in cell-based therapies due to their multipotent differentiation and immunomodulatory capacities. In consequence of limited numbers following their isolation from the donor tissue, MSCs require extensive expansion performed in traditional 2D cell culture setups to reach adequate amounts for therapeutic use. However, prolonged culture of MSCs in vitro has been shown to decrease their differentiation potential and alter their immunomodulatory properties. For that reason, preservation of these physiological characteristics of MSCs throughout their in vitro culture is essential for improving the efficiency of therapeutic and in vitro modeling applications. With this objective in mind, many studies already investigated certain parameters for enhancing current standard MSC culture protocols with regard to the effects of specific culture media components or culture conditions. Although there is a lot of diversity in the final therapeutic uses of the cells, the primary stage of standard isolation and expansion is imperative. Therefore, we want to review on approaches for optimizing standard MSC culture protocols during this essential primary step of in vitro expansion. The reviewed studies investigate and suggest improvements focused on culture media components (amino acids, ascorbic acid, glucose level, growth factors, lipids, platelet lysate, trace elements, serum, and xenogeneic components) as well as culture conditions and processes (hypoxia, cell seeding, and dissociation during passaging), in order to preserve the MSC phenotype and functionality during the primary phase of in vitro culture.

show abstract

TESSEE – Tool for Early Stem Cells Economic Evaluation

2019

View full text Add to dashboard Cite

Cost effectiveness analysis of allogeneic, just-in-time expansion of mesenchymal stem cells with PLUS™ human platelet lysate for a clinical trial

Cited by 4 publications

References 0 publications

Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review

Challenges in Clinical Development of Mesenchymal Stromal/Stem Cells: Concise Review

Towards Physiologic Culture Approaches to Improve Standard Cultivation of Mesenchymal Stem Cells

TESSEE – Tool for Early Stem Cells Economic Evaluation

Contact Info

Product

Resources

About